Press

11.04.2009

NovaRx Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix® Study

05.08.2009

Lucanix featured on MSN Health

04.15.2009

NCI’s SBIR and STTR Programs Feature NovaRx as Key Success Story

12.29.2008

Serbia First in Europe to Participate in Phase III Trial of Lung Cancer Vaccine

12.10.2008

Lung Cancer Vaccine Giving Patients New Hope

08.22.2008

Vaccine Strong in Tests

08.21.2008

Lung Cancer Vaccine Shows Great Promise

08.21.2008

NovaRx Moves into Phase III with Cancer Vaccine Lucanix

08.21.2008

NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients

05.01.2008

NovaRx Selects ISI's eCTDXPress and ISIWriter

06.09.2006

Tiny NovaRx Getting Noticed

06.05.2006

Lucanix Phase II Clinical Data Demonstrates Significantly Increased Survival in Lung Cancer Patients

05.31.2006

NovaRx To Present Lucanix® Phase II Clinical Data at ASCO

09.08.2004

The Immune Response Corporation and NovaRx Corporation Announce Revision of Licensing Agreement for Cancer Cell Line Vaccines

05.18.2004

NovaRx Achieves Full Enrollment of its Phase II Clinical Trial in Non-Small Cell Lung Cancer Ahead of Schedule

05.12.2004

NovaRx Announces $2.2 million Award of SBIR Grant to Help Fund its Pivotal Phase II/III Clinical Trial in Brain Cancer